Liqiong Song1, Yuchun Xiao1, Xianping Li1, Yuanming Huang1, Guangxun Meng2, Zhihong Ren1. 1. State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Research Units of Discovery of Unknown Bacteria and Function (2018 RU010), Chinese Academy of Medical Sciences, Beijing, China. 2. The Center for Microbes, Development and Health, CAS Key Laboratory of Molecular Virology & Immunology, Chinese Academy of Sciences, Institute Pasteur of Shanghai, University of Chinese Academy of Sciences, Shanghai, China.
Abstract
Objective: To explore the role of the Nlrp3 inflammasome activation in the development of hemolytic uremic syndrome (HUS) induced by Stx2 and evaluate the efficacy of small molecule Nlrp3 inhibitors in preventing the HUS. Methods: Peritoneal macrophages (PMs) isolated from wild-type (WT) C57BL/6J mice and gene knockout mice (Nlrc4 -/-, Aim2 -/-, and Nlrp3 -/-) were treated with Stx2 in vitro and their IL-1β releases were measured. WT mice and Nlrp3 -/- mice were also treated with Stx2 in vivo by injection, and the biochemical indices (serum IL-1β, creatinine [CRE] and blood urea nitrogen [BUN]), renal injury, and animal survival were compared. To evaluate the effect of the Nlrp3 inhibitors in preventing HUS, WT mice were pretreated with different Nlrp3 inhibitors (MCC950, CY-09, Oridonin) before Stx2 treatment, and their biochemical indices and survival were compared with the WT mice without inhibitor pretreatment. Results: When PMs were stimulated by Stx2 in vitro, IL-1β release in Nlrp3 -/- PMs was significantly lower compared to the other PMs. The Nlrp3 -/- mice treated by Stx2 in vivo, showed lower levels of the biochemical indices, alleviated renal injuries, and increased survival rate. When the WT mice were pretreated with the Nlrp3 inhibitors, both the biochemical indices and survival were significantly improved compared to those without inhibitor pretreatment, with Oridonin being most potent. Conclusion: Nlrp3 inflammasome activation plays a vital role in the HUS development when mice are challenged by Stx2, and Oridonin is effective in preventing HUS.
Objective: To explore the role of the Nlrp3 inflammasome activation in the development of hemolytic uremic syndrome (HUS) induced by Stx2 and evaluate the efficacy of small molecule Nlrp3 inhibitors in preventing the HUS. Methods: Peritoneal macrophages (PMs) isolated from wild-type (WT) C57BL/6J mice and gene knockout mice (Nlrc4 -/-, Aim2 -/-, and Nlrp3 -/-) were treated with Stx2 in vitro and their IL-1β releases were measured. WT mice and Nlrp3 -/- mice were also treated with Stx2 in vivo by injection, and the biochemical indices (serum IL-1β, creatinine [CRE] and blood ureanitrogen [BUN]), renal injury, and animal survival were compared. To evaluate the effect of the Nlrp3 inhibitors in preventing HUS, WT mice were pretreated with different Nlrp3 inhibitors (MCC950, CY-09, Oridonin) before Stx2 treatment, and their biochemical indices and survival were compared with the WT mice without inhibitor pretreatment. Results: When PMs were stimulated by Stx2 in vitro, IL-1β release in Nlrp3 -/- PMs was significantly lower compared to the other PMs. The Nlrp3 -/- mice treated by Stx2 in vivo, showed lower levels of the biochemical indices, alleviated renal injuries, and increased survival rate. When the WT mice were pretreated with the Nlrp3 inhibitors, both the biochemical indices and survival were significantly improved compared to those without inhibitor pretreatment, with Oridonin being most potent. Conclusion:Nlrp3 inflammasome activation plays a vital role in the HUS development when mice are challenged by Stx2, and Oridonin is effective in preventing HUS.
Authors: A D O'Brien; V L Tesh; A Donohue-Rolfe; M P Jackson; S Olsnes; K Sandvig; A A Lindberg; G T Keusch Journal: Curr Top Microbiol Immunol Date: 1992 Impact factor: 4.291
Authors: Amit X Garg; Rita S Suri; Nick Barrowman; Faisal Rehman; Doug Matsell; M Patricia Rosas-Arellano; Marina Salvadori; R Brian Haynes; William F Clark Journal: JAMA Date: 2003-09-10 Impact factor: 56.272
Authors: Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill Journal: Nat Med Date: 2015-02-16 Impact factor: 53.440
Authors: Veit Hornung; Andrea Ablasser; Marie Charrel-Dennis; Franz Bauernfeind; Gabor Horvath; Daniel R Caffrey; Eicke Latz; Katherine A Fitzgerald Journal: Nature Date: 2009-01-21 Impact factor: 49.962